NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced a partnership with Cure Forward, a company that aims to provide patients greater access to their genomic test results.
The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples. The test aids clinicians in choosing optimal therapies for their patients and can accelerate patient enrollment in clinical trials.
Patients enrolled in Cure Forward and tested with ClearID will have direct access to their data. The test must be ordered by a physician.